Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00226954 · ClinicalTrials.gov registry record · Phase 2
Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer
A Phase 2 study, sponsored by Stanford University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT00226954: Clinical Trial Phase 2 study, sponsored by Stanford University.
NCT00226954 is a Phase 2 study that was terminated before completion, run by Stanford University. The registered enrollment target is 23 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00226954, a Phase 2 study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
Primary: To determine the duration of use of zoledronic acid in improving Bone mineral density in patients with prostate cancer who are on hormones intermittently. Secondary Objectives: To describe the safety and tolerability at this dose and schedule
Interventions
- DRUG zoledronic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2003-03 |
| Est. Completion | 2009-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00226954
The ClinicalTrials.gov registry entry for NCT00226954 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which zoledronic acid is the first listed.
NCT00226954 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00226954 about?
NCT00226954 is a clinical study titled "Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer". Primary: To determine the duration of use of zoledronic acid in improving Bone mineral density in patients with prostate cancer who are on hormones intermittently. Secondary Objectives: To describe the safety and tolerability at this dose and schedule
What is the current status of trial NCT00226954?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2003-03. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00226954?
The interventions under investigation include: zoledronic acid (DRUG).
Who is sponsoring clinical trial NCT00226954?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.